{"id":"NCT01215513","sponsor":"Ferring Pharmaceuticals","briefTitle":"Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients","officialTitle":"An Open-Label, Multi-Centre, Extension Trial, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients Requiring Androgen Ablation Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2012-04","completion":"2012-04","firstPosted":"2010-10-06","resultsPosted":"2013-05-22","lastUpdate":"2013-05-22"},"enrollment":127,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Degarelix","otherNames":[]}],"arms":[{"label":"Degarelix","type":"EXPERIMENTAL"}],"summary":"This is an open-label, multi-centre single arm trial to investigate long-term safety and tolerability of degarelix in Korean patients with prostate cancer.","primaryOutcome":{"measure":"Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables","timeFrame":"From baseline (day 0) to end of treatment (up to day 364)","effectByArm":[{"arm":"Degarelix","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":11,"countries":["South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":156},"commonTop":["Injection site pain","Hyperhidrosis","Upper respiratory tract infection","Constipation","Injection site erythema"]}}